CircDENND2D Inhibits PD-L1-Mediated Non-Small Cell Lung Cancer Metastasis and Immune Escape by Regulating miR-130b-3p/STK11 Axis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CircDENND2D Inhibits PD-L1-Mediated Non-Small Cell Lung Cancer Metastasis and Immune Escape by Regulating miR-130b-3p/STK11 Axis

Published:2023-05-24 Issue:6 Volume:61 Page:2691-2709
ISSN:0006-2928
Container-title:Biochemical Genetics
language:en
Short-container-title:Biochem Genet

Author:

Chen Yongxing,Chen Xianshan,Li Zhao,Zhu Yike,Liu Fujin,Cai Junhong

Funder

Hainan Provincial Natural Science Foundation of China

Hainan Province Clinical Medical Center

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,General Medicine,Ecology, Evolution, Behavior and Systematics,Biochemistry

Link

https://link.springer.com/content/pdf/10.1007/s10528-023-10401-0.pdf

Reference42 articles.

1. Aggarwal C et al (2020) Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 26:2354–2361. https://doi.org/10.1158/1078-0432.CCR-19-3663

2. Anagnostou VK, Brahmer JR (2015) Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 21:976–984. https://doi.org/10.1158/1078-0432.CCR-14-1187

3. Biton J et al (2018) TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res 24:5710–5723. https://doi.org/10.1158/1078-0432.CCR-18-0163

4. Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

5. Borghaei H et al (2021) Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 39:723–733. https://doi.org/10.1200/JCO.20.01605

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3